- ... 7 and, with the expanding role of pharmacists, focusing on involving community pharmacists. 16 ... on the emergent evidence, STOPP appears to be most effective in reducing ...
- ... clinical benefit over harm (clinical effectiveness) was considered, focusing ... evidence (evidence quality). Secondly, the committee assessed whether the ...
- ... clinical benefit over harm (clinical effectiveness) was considered, focusing ... evidence (evidence quality). Secondly, the committee assessed whether the ...
- ... clinical benefit over harm (clinical effectiveness) was considered, focusing ... evidence (evidence quality). Secondly, the committee assessed whether the ...
- ... clinical benefit over harm (clinical effectiveness) was considered, focusing ... evidence (evidence quality). Secondly, the committee assessed whether the ...
- ... clinical benefit over harm (clinical effectiveness) was considered, ... in the evidence (evidence quality). Secondly, the GDG assessed whether the ...
- ... clinical benefit over harm (clinical effectiveness) was considered, ... in the evidence (evidence quality). Secondly, the GDG assessed whether the ...
- ... clinical benefit over harm (clinical effectiveness) was considered, ... in the evidence (evidence quality). Secondly, the GDG assessed whether the ...
- ... include obsessive behaviors, difficulty forming friendships, and problems focusing attention. Sleep problems, such as trouble falling asleep ... outcomes of monoamine oxidase deficiency: preclinical and clinical evidence. Int Rev Neurobiol. 2011;100:13-42. doi: ...
- ... article on PubMed Central Wojciechowski R, Hysi PG. Focusing in on the complex genetics of myopia. PLoS ...